Playlist

Traffic Restrictions Announced on Several Streets in Ashgabat

19 Sep. 11:44

In preparation for the 30th anniversary of Turkmenistan's neutrality, major beautification and infrastructure work is being carried out in Ashgabat. As a result, temporary traffic restrictions will be implemented on several streets and avenues, according to the city administration via Turkmenportal.

Traffic will be partially restricted on the following sections:

  • Until October 30: Bitarap Turkmenistan Avenue — from the Neutrality Monument to Atamurat Niyazov Avenue;

  • September 20–30: area near the “Ten Horses” monument and Chary Nurymov Street — from Alisher Navoi Street to Saparmurat Turkmenbashi Avenue;

  • September 20 – October 2: Galkynysh Street — from S.Turkmenbashi Avenue to Sona Myradova Street;

  • September 27 – October 12: Gorogly Street — from Atamurat Niyazov Avenue to Alty Garlyyev Street;

  • October 1 – November 1: Chandybil Avenue — from Bitarap Turkmenistan Avenue to Nurmuhammet Andalyp Street;

  • October 10–25: A.Annayev Street — from Gurbansoltan Eje Avenue to Azadi Street;

  • October 15 – November 1: Gurbannazar Ezizov Street — from Independence Avenue to Ataturk Street;

  • October 23 – November 1: Sona Myradova Street — from Magtymguly Avenue to Atamurat Niyazov Avenue;

  • October 31 – November 5: Saparmurat Turkmenbashi Avenue — from Gurbansoltan Eje Avenue to Magtymguly Avenue;

  • November 1–15: Sahy Jepbar Street — from Independence Avenue to Ataturk Street;

  • November 4–10: Magtymguly Avenue — from N.Andalyp Street to Mekdepler Street;
    and Andalyp Street — from Magtymguly Avenue to the Erkanalyk roundabout and Kemine Street;

  • November 15–30: Alisher Navoi Street — from Independence Avenue to Gurbansoltan Eje Avenue.

Residents and visitors are advised to plan routes accordingly and consider possible delays.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌

Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds

Today in 02:02

Source

Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.

Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌